Disclosed are improved pharmaceutical formulations comprising
dehydroepiandrosterone (DHEA), enriched in selected polymorphic forms,
for therapeutic applications. In one embodiment, the formulation
comprises, in solid form, DHEA, at least 85% of which is present as a
single polymorph selected from the form I polymorph or the form II
polymorph, and at least one pharmaceutical excipient. Methods for making
and using such compositions are also disclosed.